Get the Stockscreener App
1.69
3.43%
-0.06
After Hours:
1.67
-0.02
-1.18%
Ovid Therapeutics Inc stock is traded at $1.69, with a volume of 1.59M.
It is down -3.43% in the last 24 hours and down -6.63% over the past month.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
See More
Previous Close:
$1.75
Open:
$1.7
24h Volume:
1.59M
Relative Volume:
1.01
Market Cap:
$120.35M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-2.2533
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
+7.64%
1M Performance:
-6.63%
6M Performance:
+141.43%
1Y Performance:
+138.10%
1-Day Range:
$1.66
$1.75
1-Week Range:
$1.48
$1.77
52-Week Range:
$0.2425
$2.01
Ovid Therapeutics Inc Stock (OVID) Company Profile
Name
Ovid Therapeutics Inc
Sector
Industry
Phone
212-776-4381
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Compare OVID with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OVID
Ovid Therapeutics Inc
|
1.69 | 124.62M | 391.70K | -52.34M | -45.92M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
814.74 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
357.98 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.32 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-11-25 | Initiated | Roth Capital | Buy |
| Nov-17-25 | Initiated | Leerink Partners | Outperform |
| Oct-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-08-25 | Resumed | B. Riley Securities | Buy |
| Jun-18-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-30-24 | Initiated | B. Riley Securities | Buy |
| Apr-29-24 | Initiated | H.C. Wainwright | Buy |
| Apr-05-24 | Initiated | Wedbush | Outperform |
| Dec-21-23 | Initiated | BTIG Research | Buy |
| Oct-13-23 | Initiated | Oppenheimer | Outperform |
| Apr-20-21 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-03-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-02-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-20 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-04-19 | Initiated | RBC Capital Mkts | Outperform |
| Apr-20-18 | Initiated | Ladenburg Thalmann | Buy |
View All
Ovid Therapeutics Inc Stock (OVID) Latest News
Does Ovid Therapeutics Inc. have declining or rising EPSWeekly Trend Report & Weekly Stock Breakout Alerts - mfd.ru
Why Ovid Therapeutics Inc. (1OT) stock stays on top picksTrading Volume Trends & Use Time as Your Investing Ally - bollywoodhelpline.com
Investment Recap: Will Ovid Therapeutics Inc announce a stock splitEntry Point & Expert Curated Trade Ideas - baoquankhu1.vn
What is the target price for Ovid Therapeutics Inc. stockQuarterly Trade Summary & Weekly Top Gainers Alerts - bollywoodhelpline.com
Sectors Review: Is Ovid Therapeutics Inc stock risky to hold now2025 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Risk Hedge: Will BMBL benefit from AI trends2025 Price Action Summary & AI Powered Market Entry Ideas - baoquankhu1.vn
Why is Ovid Therapeutics Inc stock going upEarnings Risk Summary & Low Drawdown Trading Techniques - baoquankhu1.vn
Can Ovid Therapeutics Inc. (1OT) stock sustain breakout momentumJuly 2025 Summary & Fast Exit/Entry Strategy Plans - bollywoodhelpline.com
Aug Analyst Calls: What risks investors should watch in Ovid Therapeutics Inc stockWeekly Trading Summary & Verified Technical Signals - Bộ Nội Vụ
Market Review: Does Ovid Therapeutics Inc stock have upside surprise potential - baoquankhu1.vn
How Ovid Therapeutics Inc. stock performs in weak economyMarket Growth Review & Accurate Entry/Exit Alerts - Улправда
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Published on: 2026-01-09 08:22:12 - Улправда
Is Ovid Therapeutics Inc. (1OT) stock safe for risk averse investorsWeekly Trade Report & Real-Time Volume Trigger Notifications - Улправда
Why hedge funds are buying Ovid Therapeutics Inc. stockQuarterly Trade Summary & Technical Analysis for Trade Confirmation - Улправда
Can Ovid Therapeutics Inc. stock hit record highs againQuarterly Investment Review & Weekly Consistent Profit Watchlists - Улправда
Will Ovid Therapeutics Inc. stock benefit from upcoming earnings reports2025 Buyback Activity & Reliable Price Action Trade Plans - Улправда
Aug Spikes: Can Ovid Therapeutics Inc 1OT stock sustain breakout momentumEarnings Overview Report & Safe Capital Growth Stock Tips - Bộ Nội Vụ
How Ovid Therapeutics Inc. stock reacts to oil prices2026 world cup usa national team qualification goalkeepers low block defense knockout prediction statistical analysis - ulpravda.ru
Ovid Therapeutics (OVID) Price Target Increased by 22.06% to 4.23 - MSN
Is Ovid Therapeutics Inc. stock positioned well for digital economy2026 world cup usa national team round of 32 defensive leaders low block defense group prediction preview - ulpravda.ru
Ovid Therapeutics Sells Ganaxolone Royalty Rights for $7M to Immedica Pharma - MSN
OVID SEC FilingsOvid Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Ovid Therapeutics is a buy, this analyst says - Cantech Letter
Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold" - MarketBeat
Ovid Therapeutics (STU:1OT) EV-to-FCF : -2.91 (As of Dec. 26, 2025) - GuruFocus
Ovid Therapeutics (STU:1OT) EV-to-OCF : -2.91 (As of Dec. 27, 2025) - GuruFocus
Promising Penny Stocks To Watch In December 2025 - simplywall.st
FY2025 Earnings Forecast for OVID Issued By Lifesci Capital - MarketBeat
LifeSci Capital Initiates Coverage of Ovid Therapeutics (OVID) with Outperform Recommendation - Nasdaq
Form 424B3 Ovid Therapeutics Inc. - StreetInsider
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Ovid Therapeutics (OVID) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Ovid Therapeutics (NASDAQ:OVID) Earns Outperform Rating from Analysts at Lifesci Capital - MarketBeat
Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
OVID: HC Wainwright Reiterates Buy Rating with $2.00 Price Targe - GuruFocus
HC Wainwright & Co. Reiterates Ovid Therapeutics (OVID) Buy Recommendation - Nasdaq
Is Ovid Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
How Ovid Therapeutics Inc. (1OT) stock stacks up against competitorsWeekly Trade Report & Smart Investment Allocation Insights - Улправда
Will Ovid Therapeutics Inc. stock recover faster than peersGold Moves & Real-Time Volume Triggers - DonanımHaber
Is Ovid Therapeutics Inc. stock a smart buy before Fed meetingWatch List & Safe Entry Trade Reports - Улправда
Ovid Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
Takeda’s Zasocitinib Marks Another Win In Late-Stage Pipeline Strategy - Citeline News & Insights
Ovid’s KCC2 activator shows promising safety in early trial By Investing.com - Investing.com Nigeria
Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data - TipRanks
Ovid Therapeutics announces phase 1 results for Ov350 - marketscreener.com
Ovid Therapeutics Inc Reports Phase 1 Results for OV350 - TradingView — Track All Markets
Ovid’s KCC2 activator shows promising safety in early trial - Investing.com
Ovid Therapeutics Reports Phase 1 Results for the - GlobeNewswire
Ovid Therapeutics (NASDAQ:OVID) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Aug Big Picture: How analysts rate Ovid Therapeutics Inc stock todayWeekly Loss Report & Technical Confirmation Alerts - moha.gov.vn
Ovid Therapeutics Inc Stock (OVID) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.92%
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):